Stream Bio, a UK-based company that develops and manufactures a range of life science products, has unveiled a new project after winning funding through SBRI Healthcare’s Urgent and Emergence Care competition.

The project aims to develop a high-sensitivity quantitative and rapid point-of-care lateral flow diagnostic test for cardiac troponin I and troponin T – indicators of a heart attack.

A high-sensitivity troponin point-of-care lateral flow test could improve efficiency in the NHS, reduce costs, enable earlier interventions, and prevent unnecessary hospital admissions.

Stream Bio aims to address this need through the application of its novel, highly sensitive diagnostic platform. The platform will use Stream Bio’s bright and sensitive fluorescent nanotechnology – Conjugated Polymer Nanoparticles – in a lateral flow assay.

The additional funding allows the company to adapt the system for cardiac biomarkers.

CEO Andy Chaloner said: “We’re extremely excited to be exploring the potential of our diagnostic platform for use in NHS urgent care, and very proud that SBRI Healthcare has recognised the potential of our technology.

“With this funding and support, we can develop our rapid, robust and portable testing system for MI, enabling key decisions to be made much more quickly at the point of care.

“This will benefit both patients and the health service in terms of time, cost and patient outcome.”